Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCO:4157'
s FCF Margin % Range Over the Past 10 Years
Min: -1711.06 Med: -95.64 Max: 47.68
Current: 6.33
During the past 13 years, the highest FCF Margin % of TaiGen Biopharmaceuticals Holdings was 47.68%. The lowest was -1711.06%. And the median was -95.64%.
ROCO:4157's FCF Margin % is ranked better than 79.79% of 950
companies
in the Biotechnology industry
Industry Median: -81.28
vs ROCO:4157: 6.33
TaiGen Biopharmaceuticals Holdings FCF Margin % Related Terms
TaiGen Biopharmaceuticals Holdings FCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4157 vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, TaiGen Biopharmaceuticals Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TaiGen Biopharmaceuticals Holdings FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TaiGen Biopharmaceuticals Holdings's FCF Margin % distribution charts can be found below:
* The bar in red indicates where TaiGen Biopharmaceuticals Holdings's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TaiGen Biopharmaceuticals Holdings (ROCO:4157) has a FCF Margin % of 19.14% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors. According to the industry distribution chart, TaiGen Biopharmaceuticals Holdings ranks #192 out of 950 companies in the Biotechnology industry, placing it in the top 20.2%.
Is TaiGen Biopharmaceuticals Holdings' FCF Margin % too high?
TaiGen Biopharmaceuticals Holdings' current FCF Margin % is 19.14%. Based on the distribution chart, TaiGen Biopharmaceuticals Holdings ranks #192 out of 950 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, TaiGen Biopharmaceuticals Holdings has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiGen Biopharmaceuticals Holdings' FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiGen Biopharmaceuticals Holdings ranks #192 out of 950 companies for FCF Margin %. This places TaiGen Biopharmaceuticals Holdings in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors. TaiGen Biopharmaceuticals Holdings's current FCF Margin % is 19.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiGen Biopharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings (ROCO:4157) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$34.16, compared to a current price of NT$8.87 — trading 74% below its estimated fair value. The current FCF Margin % is 19.14%. TaiGen Biopharmaceuticals Holdings' overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For TaiGen Biopharmaceuticals Holdings (ROCO:4157), the current FCF Margin % is 19.14% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TaiGen Biopharmaceuticals Holdings (ROCO:4157) Overvalued in 2026?
Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings stock appears to be undervalued.
The current stock price of NT$8.87 is trading 74% below its estimated GF Value™ of NT$34.16.
GuruFocus considers TaiGen Biopharmaceuticals Holdings to be Significantly Undervalued.
Key valuation signals for ROCO:4157:
FCF Margin %: 19.14%
GF Value™: NT$34.16 vs. price of NT$8.87 (74% below fair value)
No single metric tells the full story. See the ROCO:4157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TaiGen Biopharmaceuticals Holdings Business Description
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other. The majority of the revenue is generated from development, research and sales of new drugs.
59GF Score
Get the complete analysis for ROCO:4157
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4157 has been successfully added to your 
